Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

CTMX


Fundamental

Company: CytomX Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: 3.71
EPS (ttm): 0.57
Insider Own: 17.12%
Shs Outstand: 164.91M
Perf Week: -8.23%
Market Cap: 349.62M
Forward P/E: -
EPS next Y: -0.31
Insider Trans: -0.57%
Shs Float: 120.75M
Perf Month: -11.11%
Enterprise Value: 198.41M
PEG: -
EPS next Q: -0.05
Inst Own: 63.75%
Short Float: 19.84%
Perf Quarter: 4.43%
Income: 47.98M
P/S: 2.48
EPS this Y: -86.47%
Inst Trans: 260.08%
Short Ratio: 8.27
Perf Half Y: 166.23%
Sales: 141.10M
P/B: 2.92
EPS next Y Percentage: -708.92%
ROA: 28.71%
Short Interest: 23.96M
Perf YTD: 105.83%
Book/sh: 0.73
P/C: 2.21
EPS next 5Y: -
ROE: 108.21%
52W High: 3.10 -31.50%
Perf Year: 82.76%
Cash/sh: 0.96
P/FCF: -
EPS past 3/5Y: - -
ROIC: 39.54%
52W Low: 0.40 430.00%
Perf 3Y: 38.56%
Dividend Est.: -
EV/EBITDA: 4.44
Sales past 3/5Y: 54.69% 19.16%
Gross Margin: 98.88%
Volatility W: 14.01%
Volatility M: 8.50%
Perf 5Y: -69.67%
Dividend TTM: -
EV/Sales: 1.41
EPS Y/Y TTM: 306.76%
Oper. Margin: 30.56%
ATR (14): 0.20
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 4.20
Sales Y/Y TTM: 18.01%
Profit Margin: 34.01%
RSI (14): 47.66
Recom: 1.43
Dividend Gr. 3/5Y: - -
Current Ratio: 4.20
EPS Q/Q: 98.44%
SMA20: -4.13%
Beta: 2.18
Target Price: 5.75
Payout: 0.00%
Debt/Eq: 0.06
Sales Q/Q: -25.71%
SMA50: -9.64%
Rel Volume: 2.65
Prev Close: 1.91
Employees: 121
LT Debt/Eq: 0.01
Earnings: Aug 07 AMC
SMA200: 56.47%
Avg Volume: 2.90M
Price: 2.12
IPO: Oct 08, 2015
Option/Short: Yes / Yes
EPS/Sales Surpr.: 100.00% -0.58%
Trades:
Volume: 7,635,077
Change: 10.99%

Technical:


Latest News:

CytomX stock slips on data for Amgen-partnered cancer drug | Seeking Alpha somewhat bearish
CTMX AMGN

Summary: CytomX Therapeutics (CTMX) shares sold off after reporting initial data from an early-stage trial for its experimental cancer therapy, CX-904, which showed partial responses in two pancreatic cancer patients.

Full article
2024-05-09T15:56:29Z
CytomX stock slips on data for Amgen-partnered cancer drug | Seeking Alpha neutral
CTMX AMGN

Summary: CytomX Therapeutics shares sold off after reporting initial data from an early-stage trial for its experimental cancer therapy, CX-904, which led to confirmed partial responses in two patients with pancreatic cancer.

Full article
2024-05-09T15:35:22Z
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update somewhat bullish
CTMX

Summary: CytomX Therapeutics, Inc. reported positive initial Phase 1a dose escalation data for CX-904, announced Phase 1 initiation for CX-2051 and CX-801, and achieved milestones under T-cell engaging bispecific collaboration. The company highlighted its leadership in developing PROBODY® therapeutics for cancer patients.

Full article
2024-05-09T11:53:48Z
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update somewhat bullish
CTMX

Summary: - CytomX Therapeutics, Inc. announced positive initial Phase 1a dose escalation data for CX-904 in solid tumors, initial data for CX-2051 expected in the first half of 2025, and initiation of Phase 1 study activities for CX-801 with Merck. The company reported upbeat progress and achieved milestones in their R&D partnerships and pipeline development. Financially, they reported increased revenue but decreased cash balance for the first quarter of 2024.

Full article
2024-05-08T20:24:22Z
Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates very bullish
PFE CTMX

Summary: U.S. stocks traded higher with Dow Jones gaining over 200 points. Pfizer reported better-than-expected first-quarter financial results. CytomX Therapeutics, Inc. shares surged 148%.

Full article
2024-05-01T18:54:29Z